Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.76 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19633152 | 0.89 | CYP1A2 (0.88) | CYP1A2CYP2D6CYP2C19TAAR1LMNA | |
| SCHEMBL29672948 | 0.85 | CYP1A2 (0.65) | CYP1A2CYP2D6CYP2C19TAAR1LMNA | |
| SCHEMBL8583518 | 0.85 | CYP1A2 (0.65) | CYP1A2CYP2D6CYP2C19TAAR1LMNA | |
| SCHEMBL1420648 | 0.84 | CYP1A2 (0.62) | CYP1A2CYP2D6CYP2C19TAAR1KDM4E | |
| SCHEMBL552961 | 0.84 | TAAR1 (0.66) | CYP1A2CYP2D6CYP2C19TAAR1L3MBTL1 | |
| SCHEMBL6364808 | 0.82 | CYP1A2 (0.61) | CYP1A2CYP2D6CYP2C19TAAR1LMNA | |
| SCHEMBL5275606 | 0.81 | CYP1A2 (0.66) | CYP1A2CYP2D6CYP2C19TAAR1SIGMAR1 | |
| SCHEMBL16619429 | 0.81 | CYP1A2 (0.61) | CYP1A2CYP2D6CYP2C19TAAR1KDM4E | |
| SCHEMBL16269355 | 0.81 | TAAR1 (0.62) | CYP1A2CYP2D6CYP2C19TAAR1CARM1 | |
| SCHEMBL3622330 | 0.81 | CYP1A2 (0.60) | CYP1A2CYP2D6CYP2C19TAAR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6927228-B2 | Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-09 | — | — | US | disclosed |
| EP-1309575-B1 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | GALDERMA RES & DEV (FR) | 2005-06-08 | — | — | EP | disclosed |
| US-20040039038-A1 | Biaromatic compound activators of PPARy-type receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-26 | — | — | US | disclosed |
| CN-1468226-A | Biphenyl derivatives and their use as ppar-gamma receptor activators | �������о�����չ˽������˾ | 2004-01-14 | — | — | CN | disclosed |
| EP-1309575-A1 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | Galderma Research & Development (FR) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002012210-A9 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | GALDERMA RES & DEV (FR) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002012210-A1 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039038-A1 | Biaromatic compound activators of PPARy-type receptors | PPARG, PPARA, PPARD | CYP1A2 93/4885CYP2D6 294/4885CYP2C19 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.